Therapeutic alliance, a stake in schizophrenia;L'alliance thérapeutique, un enjeu dans la schizophrénie

Encephale

Volumn 35, Issue 1, 2009, Pages 80-89

  Charpentier, A ^a,b   Goudemand, M ^a   Thomas, P ^a  

^a UNIV LILLE   (France)

^b hôpital Lucien Bonafe   (France)

Author keywords

Antipsychotic agents; Compliance; Efficiency; Psychosis; Schizophrenia; Therapeutic alliance

Indexed keywords

NEUROLEPTIC AGENT;

CONSULTATION; EVIDENCE BASED MEDICINE; GENERAL PRACTITIONER; HOSPITAL READMISSION; HUMAN; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; QUALITY OF LIFE; SCHIZOPHRENIA; SHORT SURVEY; SOCIAL SUPPORT; STATISTICAL ANALYSIS;

ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FRANCE; HUMANS; LONG-TERM CARE; MEDICATION ADHERENCE; PATIENT READMISSION; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 61349185812     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2007.12.009     Document Type: Short Survey

References (65)

1. Altamura A.C. A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia. With particular reference to drug resistance. Schizophr Res 3 (1993) 187-198
2. Angermeyer M.C., and Matschinger H. Neuroleptics and quality of life. A patient survey. Psychiatr Prax 2 (2000) 64-68
3. Ascher-Svanum H., Zhu B., Faries D., et al. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry 7 (2006) 1114-1123
4. Bai Y.M., Lin C.-C., Chen J.-Y., et al. Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry 7 (2006) 1276-1279
5. Balint M. Le médecin, son malade et la maladie (1996), Payot, Paris
6. Baumann M., and Trincard M. Autonomy attitudes in the treatment compliance of a cohort of subjects with continuous psychotropic drug administration. Encéphale 5 Pt 1 (2002) 389-396
7. Benkert O., Graf-Morgenstern M., Hillert A., et al. Public opinion on psychotropic drugs: an analysis of the factors influencing acceptance or rejection. J Nerv Ment Dis 185 (1997) 151-158
8. Billups S., Malone D., and Carter B. The relationship between drug therapy non compliance and patient characteristics, health-related quality of life and health care costs. Pharmacotherapy 20 (2000) 941-949
9. Borras L., Mohr S., Brandt P.Y., et al. Religious beliefs in schizophrenia: their relevance for adherence to treatment. Schizophr Bull (2007) sbl070
10. Buckley P.E., and Evans D. First-episode schizophrenia. A window of opportunity for optimizing care and outcomes. Postgrad Med (2006) 5-19
11. Byerly M., Fisher R., Whatley K., et al. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res 2-3 (2005) 129-133
12. Claxton A.J., Cramer J., and Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 8 (2001) 1296-1310
13. Day J.C., Bentall R.P., Roberts C., et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry 7 (2005) 717-724
14. Dettling M., Anghelescu I.-G., Essock S.M., et al. Antipsychotic drugs and schizophrenia. N Engl J Med 3 (2006) 298-300
15. Droulout T., Liraud F., and Verdoux H. Relationships between insight and medication adherence in subjects with psychosis. Encephale 5 (2003) 430-437
16. Essock S.M., Covell N.H., Davis S.M., et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry 12 (2006) 2090-2095
17. Feinstein A.R. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 7 (1990) 1377-1378
18. Fenton W., Blyler C., and Heinssen R. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 23 (1997) 637-651
19. Frank A., and Gunderson J. The role of the therapeutic alliance in the treatment of schizophrenia. Relationship to course and outcome. Arch Gen Psychiatry 47 (1990) 228-236
20. Gharabawi G.M., Greenspan A., Rupnow M.F., et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial. BMC Psychiatry (2006) 45
21. Gilmer T.P., Dolder C.R., Lacro J.P., et al. Adherence to treatment with antipsychotic medication and health care costs among medical aid beneficiaries with schizophrenia. Am J Psychiatry 4 (2004) 692-699
22. Glynn S.M., Cohen A.N., and Niv N. New challenges in family interventions for schizophrenia. Expert Rev Neurother 1 (2007) 33-43
23. Gopalakrishnan R., Jacob K.S., Kuruvilla A., et al. Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial. Am J Psychiatry 3 (2006) 494-499
24. Grossman L. A study of the capacity of schizopphrenic patients to give informed consent. Hosp Community Psychiatry 31 (1980) 205-206
25. Hamann J., Langer B., Leucht S., et al. Medical decision making in antipsychotic drug choice for schizophrenia. Am J Psychiatry 7 (2004) 1301-1304
26. Hofer A., Kemmler G., Eder U., et al. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry 1 (2002) 49-53
27. Hogan T.P., Awad A.G., and Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1 (1983) 177-183
28. Johnstone E.C., and Geddes J. How high is the relapse rate in schizophrenia?. Acta Psychiatr Scand Suppl (1994) 6-10
29. Kampman O. Review: over 25% of people with schizophrenia, psychoses, or severe mental disorders fail to adhere to treatment programmes. Evid Based Ment Health 2 (2004) 40
30. Kampman O., Laippala P., Vaananen J., et al. Indicators of medication compliance in first-episode psychosis. Psychiatry Res 1 (2002) 39-48
31. Kikkert M.J., Schene A.H., Koeter M.W.J., et al. Medication adherence in schizophrenia: exploring patients', carers' and professionals' views. Schizophr Bull 4 (2006) 786-794
32. Lambert M., Conus P., Eide P., et al. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 7 (2004) 415-422
33. Leucht S., Wahlbeck K., Hamann J., et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 9369 (2003) 1581-1589
34. Lieberman J.A., Stroup T.S., Mcevoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 12 (2005) 1209-1223
35. Llorca P.M., Miadi-Fargier H., Lancon C., et al. Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation. Encephale 2 (2005) 235-246
36. March J.S., Silva S.G., Compton S., et al. The case for practical clinical trials in psychiatry. Am J Psychiatry 5 (2005) 836-846
37. Misdrahi D., Llorca P.M., Lancon C., et al. Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications. Encephale 3 Pt 1 (2002) 266-272
38. Misdrahi D., Verdoux H., Llorca P.M., et al. Therapeutic adherence and schizophrenia: the interest of the validation of the French translation of medication adherence rating scale (MARS). Encephale 4 (2004) 409-410
39. Nasrallah H.A., Targum S.D., Tandon R., et al. Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr Serv 3 (2005) 273-282
40. Olfson M., Mechanic D., Hansell S., et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2 (2000) 216-222
41. Osterberg L., and Blaschke T. Adherence to medication. N Engl J Med 5 (2005) 487-497
42. Pampallona S., Bollini P., Tibaldi G., et al. Patient adherence in the treatment of depression. Br J Psychiatry 2 (2002) 104-109
43. Parker R.S., and Pettijohn C.E. Pharmaceutical drug marketing strategies and tactics: a comparative analysis of attitudes held by pharmaceutical representatives and physicians. Health Mark Q 4 (2005) 27-43
44. Perkins D.O., Johnson J.L., Hamer R.M., et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res 1 (2006) 53-63
45. Pharoah F., Mari J., Rathbone J., et al. Family intervention for schizophrenia. Cochrane Database Syst Rev 4 (2006) CD000088
46. Robinson D., Woerner M.G., and Alvir J.M.J. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56 (1999) 241-247
47. Roter D.L., and Hall J.A. Strategies for enhancing patient adherence to medical recommendations. JAMA 1 (1994) 80
48. Sabate E. Adherence to long-term therapies: evidence for action. World Health Organization. http://www.who.int. 2003.
49. Spencer E., Birchwood M., and Mcgovern D. Management of first-episode psychosis. Adv Psychiatr Treat (2001) 133-142
50. Steiner J.F., and Earnest M.A. The language of medication-taking. Ann Intern Med 11 (2000) 926-930
51. Stroup T.S., Lieberman J.A., Mcevoy J.P., et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 4 (2006) 611-622
52. Teich J. The CATIE study. Am J Psychiatry 3 (2006) 554-555
53. Thompson K., Kulkarni J., and Sergejew A.A. Reliability and validity of a new medication adherence rating scale (MARS) for the psychoses. Schizophr Res 3 (2000) 241-247
54. Urquhart J. The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet 5 (1997) 345-356
55. Volz A., Khorsand V., Gillies D., et al. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev 1 (2007) CD006391
56. Ward A., Ishak K., Proskorovsky I., et al. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study. Clin Ther 11 (2006) 1912-1921
57. Watzlawick P. Les cheveux du baron de Münchhausen (1988), Seuil, Paris
58. Watzlawick P. Stratégie de la thérapie bréve (1997), Seuil, Paris
59. Weiden P., Dixon L., Frances A., et al. Neuroleptic noncompliance in schizophrenia. In Advances in Neuropsychiatry and Psychopharmacology (1991), Raven Press, New York
60. Weiden P.J., and Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 3 (1995) 419-429
61. Weiden P.J., Rapkin B., Mott T., et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull 20 (1994) 297-310
62. Wyatt R.J. Early intervention with neuroleptics may decrease the long-term morbidity of schizophrenia. Schizophr Res 3 (1991) 201-202
63. Wyatt R.J. Research in schizophrenia and the discontinuation of antipsychotic medications. Schizophr Bull 1 (1997) 3-9
64. Young J.L., Zonana H.V., and Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 2 (1986) 105-122
65. Zygmunt A., Olfson M., Boyer C.A., et al. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 10 (2002) 1653-1664 (65)